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Abstract
Introduction There is limited published evidence on duodenal carcinoma due to its rarity. This study aimed to evaluate gastric
outlet obstruction and obstructive jaundice along with pathological variables as survival factors in patients with duodenal
adenocarcinoma following resection.
Methods Survival factor analysis was undertaken in patients undergoing duodenal cancer surgery from 1997 to 2015 in a single
centre.
Results There were 57 patients of whom 18 had gastric outlet obstruction and 14 had obstructive jaundice. Fifty-three
had a partial pancreatoduodenectomy and four had palliative bypass. Perioperative mortality and morbidity were 4%
(2/53) and 47% (25/53) respectively in resected patients. With a median (95% confidence interval, CI) follow-up of 72
(57–86) months, median overall and recurrence-free survival was 38 months (95% CI 28–113) and 27 months (95% CI
18–83) respectively. The 1 and 3-year overall survival rates were 84% (95% CI 74–95) and 52% (95% CI 39–69)
respectively. Median overall survival was 19 months in patients with gastric outlet obstruction vs 53 months in those
without (p = 0.026) and 28 months in patients with obstructive jaundice vs 38 months in those without (p = 0.611).
Univariate analysis revealed that tumour stage, resection margin status, pre-operative albumin status, gastric outlet
obstruction and age were associated with poorer overall and recurrence-free survival but multivariate analysis confirmed
only tumour stage and resection margin status to be significant.
Conclusion Whereas gastric outlet obstruction in duodenal cancer appeared to be an important survival factor following partial
pancreatoduodenectomy, multivariate analysis showed that only tumour stage and resection margin status were the key inde-
pendent survival factors. Further multicentre studies are required to elucidate further characteristics of duodenal carcinoma and
develop neoadjuvant/adjuvant management strategies.
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Introduction
Duodenal adenocarcinoma is a rare malignancy; between
1998 and 2007, there were 2684 patients diagnosed in the
UK and between 1997 and 2013, there were 2436 cases diag-
noses in Germany [1]. The incidence is 0.4–0.6/105 in men
and marginally lower in women at 0.3–0.5/105 with a 1-year
survival of 35.9% and 16.1% at 5 years [2]. These survival
figures differ markedly from those in Germany and the USA.
The 1-year age-adjusted relative survival rates in Germany
and the USAwere reported as 67.2% and 68.8% respectively
and the 5-year age-adjusted relative survival rates as 44.4%
and 50.1% respectively [1]. Due to its low incidence, it is often
grouped together with small bowel malignancy which ac-
counts for 2% of all gastrointestinal tumours in the USA. Of
all small bowel adenocarcinomas, 55.7% are located within
the duodenum and 7% of periampullary tumours are duodenal
in differentiation [3–5]. This infrequency in incidence has
prevented the establishment of a thorough evidence base on
which to derive uniform management and determine clinical
and histopathological prognostic factors.
Initial clinical features are often insidious and more prom-
inent when the lesion has grown to a size that can cause com-
plications. There are vague symptoms of abdominal pain, nau-
sea, vomiting, weight loss, fatigue and anorexia with some
patients experiencing jaundice, gastrointestinal bleeding or
gastric outlet obstruction [4, 5]. Investigations commonly in-
volve direct visualisation and biopsy in the form of endoscopy
or cross-sectional computed tomography imaging. Patients
may have to undergo stenting via endoscopic retrograde
cholangiopancreatography to provide relief of jaundice or re-
quire enteral or parenteral nutritional support. Surgical resec-
tion remains the mainstay of curative treatment, in the form of
pancreatoduodenectomy or in rarer cases segmental duodenal
resection [3]. Patients who have dysplastic duodenal polyps,
either single or part of a hereditary condition such as familial
adenomatous polyposis, may have undergone submucosal re-
section or a pancreas-preserving duodenectomy [6, 7]. There
is very little published evidence regarding the use of
neoadjuvant/adjuvant chemotherapy or radiotherapy. Some
centres have treated duodenal adenocarcinoma similarly to
periampullary tumours and use fluorouracil-based therapy
and others as a colorectal malignancy and use oxaliplatin-
based treatments [4, 5, 8, 9].
Due to the small number of cases, it has proved difficult to
confidently identify survival factors although tumour size,
lymph node status and resection margin status have often
mentioned [5, 10–13]. In a single-centre study from Korea,
the prognostic factors of 36 patients with duodenal cancer
were analysed to find clear resection margin (R0), symptoms
at initial admission, presence of lymph node metastasis, and
perineural invasion significant only on univariate analysis
[10]. The aim of this study was to include the specific
presenting clinical features of obstructive jaundice and gastric
outlet obstruction as part of the univariate and multivariate
analysis of predictive survival factors.
Material and methods
All patients undergoing surgical exploration with a view to
partial pancreatoduodenectomy for presumed duodenal carci-
noma from 1 January 1997 to 31 December 2015 at the Royal
Liverpool University Hospital were reviewed from a prospec-
tively maintained pancreatobiliary database. Hereditary dys-
plastic duodenal polyps, ampullary tumours of duodenal ori-
gin and neuroendocrine lesions were excluded from the study.
Data were obtained retrospectively from patient case notes
and electronic records.
Data retrieved included patient demographics, timing of
management, peri/post-operative details, tumour histology
and stage, length of stay, adjuvant treatment, re-interventions/
readmissions and survival data. The TNM staging was
standardised to the latest UICC version 8 [14]. Time to opera-
tion parameters are from initial diagnostic investigation to date
of procedure and includes the time to multidisciplinary meet-
ing. Length of stay results are overall time in the hospital in-
clusive of early pre-operative admissions. Post-operative com-
plications were reported according to the Clavien-Dindo clas-
sification [15]. Patients who had a raised bilirubin of greater
than 40 μmol/L were considered to have obstructive jaundice,
and a record was made of pre-operative endoscopic retrograde
cholangiopancreatography (ERCP) and percutaneous
transhepatic cholangiography (PTC). Those patients admitted
or transferred to this institution with symptoms of persistent
vomiting and being unable to tolerate diet, correlating with an
obstructive diagnosis on gastroscopy or oral contrast computer
tomography (CT) were recorded as gastric outlet obstruction.
Continuous variables are presented with their median and
interquartile range (IQR), while categorical variables are de-
scribed as frequency counts and proportion percentages. The
Fisher exact test or Wilcoxon-Mann-Whitney test were per-
formed as appropriate in order to compare proportions and
distributions. Survival analysis was carried out for time to
death and time to recurrence. Time to death was defined as
the difference between date of death (or latest follow-up visit
for living patients) and date of diagnosis. Time to recurrence
was defined as the difference between the date of imaging
demonstrating recurrence or date of death (or latest follow-
up visit for living patients free from recurrence) and date of
operation. For both these responses, median survival estimates
from Kaplan-Meier method and their 95% confidence inter-
vals (CIs) are reported. Cox proportional hazard models were
initially fitted for each covariate independently and are pre-
sented as hazard ratios (HR) with 95% CI [16]. Prognostic
factors with a p value less than 0.05 were further explored in
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multivariable settings using backward selection technique
based on Akaike Information Criterion for selecting the best
model [17]. Proportional hazard assumption for Cox models
was assessed with Schoenfeld residuals [18]. Kaplan-Meier
curves and log-rank test were applied to investigate the differ-
ence in survival distribution between the clinical subgroup of
interest. Median follow-up time was estimated with the re-
verse Kaplan-Meier method [19]. A p value less than 0.05
was considered to be significant. All statistical analyses were
performed with R version 3.3.0.
Results
There were 57 patients who had an attempted partial
pancreatoduodenectomy for duodenal adenocarcinoma during
the 18-year study period. The median age was of 71 (IQR
63.0–74.0) years and the female to male ratio of 1:0.78.
Median time from the diagnosis to date of operation was 41
(IQR 32.0–54.5) days. Eighteen (32%) patients presented with
gastric outlet obstruction, and 12 of them were admitted prior
to operation for enteral or parenteral nutritional support. There
Table 1 Patient cohort characteristics
Total Gastric outlet obstruction Obstructive jaundice
N = 57 N = 51 N = 52
No Yes p value No Yes p value
n = 33 n = 18 n = 38 n = 14
Gender
Female 32 (56%) 13 (39%) 10 (56%) 0.378 16 (42%) 7 (50%) 0.755
Male 25 (44%) 20 (61%) 8 (44%) 22 (58%) 7 (50%)
Age (years)
Median 71 71 69 0.252 710 74 0.129
IQR (63.0–74.0) (66.0–74.0) (60.0–72.8) (63.2–73.0) (68.2–75.5)
Time to operation (days)
Median 41 47 32 0.001 40 48 0.323
IQR (32.0–54.5) (36.0–58.0) (25.0–41.0) (30.5–48.8) (35.0–57.0)
No. of observations available 47 29 17 34 13
Length of stay (days)
Median 26 18 40 0.001 23 32 0.146
IQR (15.5–40.5) (13.5–31.0) (31.2–47.5) (14.0–39.0) (21.2–49.0)
No. of observations available 47 31 16 33 14
Table 2 TNMstaging for patients
undergone successful resection Total Gastric outlet obstruction Obstructive jaundice
N = 53 N = 47 N = 48
No Yes p value No Yes p value
n = 31 n = 16 n = 37 n = 11
T stage
1 2 (4%) 2 (6%) 0 (0%) 0.068 1 (3%) 1 (9%) 0.569
2 7 (13%) 7 (23%) 0 (0%) 5 (14%) 2 (18%)
3 15 (28%) 6 (19%) 7 (44%) 12 (32%) 2 (18%)
4 29 (55%) 16 (52%) 9 (56%) 19 (51%) 6 (55%)
N stage
0 17 (32%) 10 (32%) 6 (38%) 0.794 12 (32%) 4 (36%) 0.217
1 21 (40%) 13 (42%) 5 (31%) 12 (32%) 6 (55%)
2 15 (28%) 8 (26%) 5 (31%) 13 (35%) 1 (9%)
R status
0 43 (81%) 28 (90%) 9 (56%) 0.020 28 (76%) 10 (91%) 0.416
1 10 (19%) 3 (10%) 7 (44%) 9 (24%) 1 (9%)
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were significantly lower levels of pre-operative serum albu-
min in patients presenting with gastric outlet obstruction com-
pared to those without 34.0 (IQR 34.0–42.0) vs 38.0 (IGR
27.5–37.8) g/L, respectively, p = 0.014. Fourteen patients
(25%) presented at this or local institutions with obstructive
jaundice and eight of them had successful pre-operative ERCP
and stenting. Five patients had successful PTC and stenting,
with a single failure. Despite these interventional procedures,
there were still six patients who had bilirubin levels >
100 μM/L on the day of operation. Information was not re-
corded in six patients with gastric outlet obstruction and five
with obstructive jaundice respectively (Fig. 1). There were
four patients who had both gastric outlet obstruction and ob-
structive jaundice but, for the purpose of this analysis, these
were treated separately. Median time to operation was signif-
icantly shorter in patients with gastric outlet obstruction than
without, 32 (IQR 25.0–41.0) days vs 47 (IQR 36.0–58.0) days
respectively [U = 390, p value = 0.001] (Table 1).
Fifty-three (93%) patients underwent a curative resection,
and four (7%) had a palliative gastric/biliary bypass procedure
for local invasion or metastatic spread. Fifteen (28%)
patients undergoing resection had a classic Kausch Whipple
procedure, and 38 (72%) had a pylorus preserving
pancreatoduodenectomy with three patients requiring a right
hemicolectomy to complete tumour resection. A single patient
had a splenectomy because of a suspicious lesion on pre-
operative staging, which was actually a lymphangioma. All
histopathology results were collated including confirmation
biopsies for patients in the bypass group. Fifty resected spec-
imens were intestinal type duodenal carcinoma; two were mu-
cinous type cancer and one with signet cell carcinoma. Nine
patients (17%) had tumour (T) staging of 1 or 2, 36 patients
(68%) had lymph node (LN) involvement and 43 patients
(81%) had tumour free resection margins (R0). It is worth
noting that patients who had a right hemicolectomy were not
more prevalent within a gastric outlet obstruction or obstruc-
tive jaundice group (Table 2).
There were two (4%) post-operative deaths following re-
section both due to myocardial infarction. There were 30 post-
operative complications in 24 (47%) patients: 21 Clavien-
Dindo grade II, six with grade III and three with grade IV.
Fourteen (26%) patients had intra-abdominal collections, of
which six (11%) were associated with pancreatic leaks and
they were managed conservatively with antibiotics in eight
cases and interventional drainage in six cases. There were
three incidences of delayed gastric emptying (6%) that re-
quired total parenteral nutrition. The remaining post-
operative morbidities consisted of six (11%) patients with sur-
gical site infections, five (9%) patients with respiratory com-
plications, one (2%) patient with an acute kidney injury and
one (2%) patient with an upper arm deep vein thrombosis. No
significant differences in post-operative course or complica-
tions rates were found in patients presenting with gastric outlet
obstruction or obstructive jaundice compared to those without
either. The median length of total hospital stay (which includ-
ed pre-operative admission for nutritional supplementation) in
Paents having aempted a pancreatoduodenectomy 
for duodenal adenocarcinoma
(N=57)
Paents available for Obstrucve 
Jaundice subgroup analysis
(N=48)
Paents available for Gastric Outlet 
Obstrucon subgroup analysis
(N=47)
Paents with Gastric Outlet Obstrucon (n=18)
Paents without Gastric Outlet Obstrucon (n=29)
Missing informaon on Gastric Outlet Obstrucon (n=6)
Paents available for survival analysis
(N=50)
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Fig. 1 A CONSORT flow
diagram demonstrating the
cohorts of patients with
obstructive jaundice and gastric
outlet obstruction
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patients with gastric outlet obstruction was 40 (IQR 31.2–
47.5) days compared to 18 (IQR 13.5–31.0) days for patients
without gastric outlet obstruction [U = 102, p value = 0.001]
(Fig. 2). The median pre-surgery length of hospital stay in
patients with gastric outlet obstruction was 13 (IQR 10.1–
26.0) days compared to 0 (IQR 0.4–5.9) days in those without
gastric outlet obstruction.
Eighteen (32%) patients underwent adjuvant chemothera-
py, and two (4%) patients had adjuvant chemoradiotherapy.
Ten were treated with capecitabine as a single therapy regi-
men, whereas three patients had gemcitabine monotherapy
and three patients had 5-fluorouracil monotherapy. A further
four patients had dual drug regimens involving folinic acid, 5-
fluorouracil, capecitabine and oxaliplatin. Thirty (53%) pa-
tients that did not receive any adjuvant chemotherapy because
of poor performance status in 16 patients, oncology advice in
nine patients, personal choice with two patients and death in
three patients. Records were not available in seven cases.
Though a lack of consistent therapies, the use of any adjuvant
therapy did not have a significant effect on patient survival,
[HR = 0.88 (95% CI 0.40–1.92), p value = 0.742].
Themedian follow-up time was 72 (95%CI 57–86) months.
The median overall survival (OS) time was 38 (95% CI 28–
113) months, with 1- and 3-year survival rates of 84% (95% CI
74–95) and 53% (95% CI 39–69) respectively. The median
recurrence-free survival (RFS) was 27 (95%CI 18–83) months,
with 1- and 3-year recurrence-free survival rates of 72% (95%
CI: 61–86) and 45% (95%CI: 33–61) respectively (Fig. 3). The
median OS time was 19 months (95% CI 11–unobtainable) in
the group of patients presenting with gastric outlet obstruction
and 53 (95% CI 31–unobtainable) months in patients present-
ing without [log-rank χ2df = 1 = 4.96, p value = 0.026] (Fig. 4a).
Although without reaching statistical significance, similar
trends were reported with respect to time to recurrence, 16
(95% CI 7–unobtainable) months vs 47 (95% CI 21–unobtain-
able) months for patients with and without gastric outlet ob-
struction respectively [log-rank χ2df = 1 = 3.13, p value =
0.077] (Fig. 4b). No differences in overall survival or
recurrence-free survival were detected between patients having
obstructive jaundice or not (Fig. 5).
Univariate Cox models showed that resection margin sta-
tus, tumour stage and pre-operative albumin levels were relat-
ed to both time to death and time to recurrence (Tables 3 and
4). Gastric outlet obstruction was also associated with overall
survival, and age was associated with recurrence-free survival.
Multivariable Cox regression identified resection margin sta-
tus [HR = 5.83 (95% CI 2.25–15.07), p value < 0.001] and
tumour stage [HR = 2.27 (95% CI 1.02–5.04), p value =
0.040] as predictive factors for overall survival (Table 5).
The best model for recurrence-free survival included resection
margin status [HR = 4.48 (95% CI 1.95–10.28), p value <
0.001], age [HR = 1.06 (95% CI 1.01–1.11), p value =
0.012] and tumour stage [HR = 2.28 (95% CI 1.07–4.86), p
value = 0.070], although the latter did not reach the signifi-
cance level in the multivariable setting (Tables 5 and 6).
Discussion
This study has shown that advanced tumour stage, positive
resection margins, low pre-operative albumin levels, the
presence of gastric outlet obstruction and advanced age
were each associated with shorter overall and recurrence-
free survival following partial pancreatoduodenectomy for
duodenal cancer. On multivariate analysis however, only
tumour stage and resection margin status were of indepen-
dent significance. This indicates that whereas gastric outlet
obstruction in duodenal cancer appeared to be an important
Fig. 2 Box plot distributions of length of stay in patients with a gastric
outlet obstruction and b obstructive jaundice preoperatively
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survival factor per se, the symptom of obstruction signified
a larger tumour diameter. The challenges in removing a
larger tumour are reflected in the greater frequency of pos-
itive margins in this group and points to the need for an
effective neoadjuvant and/or adjuvant strategy.
The Royal Liverpool University Hospital serves a
catchment area of over 400,000 people and acts as a ter-
tiary referral centre for hepatobiliary disease for a much
larger populace of approximately 2.4 million and repre-
sents a relatively large single-centre experience. This
compares to a series of 178 patients over 13 years from
six other large centres in the UK [13], whilst other studies
including those from the USA and Japan have reviewed
from 21 to 122 patients [5, 10, 12, 20–24]. In the present
study, only four (7%) patients underwent a palliative pro-
cedure which is less than that observed in two larger co-
hort studies reflecting the quality of pre-operative workup
and technical surgery [12, 13, 25]. There were only two
(4%) post-operative deaths both due to myocardial infarc-
tion. The morbidity rate of 47% is similar to those pub-
lished in previous studies of approximately 40–46% [5,
12, 13, 22, 23]. The majority (70%) of complications
were Clavien-Dindo grade II requiring only medical inter-
vention. The proportion of patients with a pancreatic leak
was 11%, in keeping with a published range of 9.3–28.9%
[5, 12, 13, 21, 22]. The delayed gastric emptying rate of
6% is lower than the reported rates of 12.5–24% [5, 12,
13, 22, 23].
The median overall survival in duodenal adenocarcinoma
is approximately 35.5–83 months in published series [5, 12,
13, 22, 23]. The median overall survival of 38 months in our
study is at the lower end of this range but much improved from
previous United Kingdom figures and recent German and US
publications [1, 2]. Negative resection margin status and
Fig. 3 Kaplan-Meier estimates of
median survival and recurrence-
free survival with 95% confi-
dence intervals of duodenal ade-
nocarcinoma patients with a gas-
tric outlet obstruction and b ob-
structive jaundice preoperatively
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tumour stage III or lower were associated with longer survival.
Published series have not consistently found lymph node sta-
tus to be a significant prognostic factor [4, 5, 12, 13, 25, 26].
Interestingly, age seemed to be a prognostic factor for
recurrence-free survival which has been described recently
in a German observational study [27]. A study of small bowel
cancers based on the USA Surveillance, Epidemiology, and
End Results (SEER) database from 2004 to 2013 found that
duodenal localization was associated with worse overall sur-
vival and that young age, retrieval of more than 12 regional
lymph nodes, less advanced stage and married matrimonial
status were positive, independent prognostic factors [1].
There is no standard of adjuvant chemotherapy in patients
with resected duodenal adenocarcinoma. In our study, 20 pa-
tients (35%) underwent chemotherapy or chemoradiotherapy,
and ten of these had the same drug regimen (capecitabine).
The ESPAC-3 periampullary trial, which included 80
intestinal type tumours, found an increase in median survival
of 7.9 months comparing a chemotherapy group (5-
fluorouracil plus folinic acid) to an observation group [28].
This is the only randomised phase three trial pertinent to du-
odenal carcinoma, but there have been three phase II studies
that have observed the benefit of chemotherapy on advanced
small bowel tumours. Response rates of 18.4% were reported
using 5-fluorouracil, doxorubicin, and mitomycin C and a rate
of 50%more recently utilising capecitabine and oxaliplatin [8,
9]. Adding irinotecan to capecitabine and oxaliplatin has giv-
en a response rate of 37% in the latest phase II trial of 33
patients [29]. Due to the lack of robust adjuvant chemotherapy
trials the rate of adjuvant therapy is quite variable [4, 5, 12,
13]. The use of radiotherapy in duodenal cancer has been
studied even less, and propensity score-matched analysis of
national observational oncological data from the US and
South Korea has been reported. They observed that radiation
Fig. 4 Kaplan-Meier estimates of
median survival by clinical sub
groups of a obstructive jaundice
and b gastric outlet obstruction
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provides minimal survival benefit in addition to adjuvant che-
motherapy but may have a role in locally advanced disease
[30, 31].
There have been no published studies specifically
reviewing the effects of obstructive jaundice and gastric outlet
obstruction on the outcomes of duodenal adenocarcinoma.
The Korean single-centre study grouped together presenting
symptoms (abdominal pain, vomiting, gastrointestinal bleed-
ing, dyspepsia, weight loss, jaundice, diarrhoea and oedema)
as part of a multivariate analysis and found no significant
prognostic factors [10]. In the present study, we included the
specific presenting clinical features of obstructive jaundice
and gastric outlet obstruction as part of the predictive model-
ling, given that one or other of these clinical features might
influence clinical decision-making. The systemic effects of
obstructive jaundice on patients with pancreatic ductal adeno-
carcinoma have been well established, and preoperative
biliary drainage with metal stenting is routine in some centres.
However, others undertake immediate resection without bili-
ary stenting and some centres are employing a Bfast track^
pathway for pancreatoduodenectomy procedures [32–35]. In
the present study, obstructive jaundice at presentation was not
associated with pathological staging, resectability, post-
operative complications and survival. Patients presenting with
gastric outlet obstruction required a longer overall length of
hospital stay to improve nutritional status. Pre-operative se-
rum albumin levels were significantly lower in these patients
with gastric outlet obstruction reflecting the nutritional deficit
and the development of a cachexia associated with cancer
[36]. Although gastric outlet obstruction was associated with
reduced survival on univariate analysis, this was not supported
once other prognostic factors were taken onto account. The
impact of gastric outlet obstruction is complex because it in-
corporates greater proportions of high tumour staging and
Fig. 5 Kaplan-Meier estimates of
median time to recurrence by
clinical sub groups of a
obstructive jaundice and b gastric
outlet obstruction
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positive resection margins which are independently signifi-
cant factors. As a presenting symptom, it reflects multiple
aspects of tumour staging and the study may be underpowered
to demonstrate its significance. Its importance should not be
overlooked and efficient pre-optimisation and meticulous op-
erative preparations should be undertaken.
The limitations of this study are the relatively small number
of patients and its retrospective nature. The study is strength-
ened however in being from a single centre and with sufficient
number of events for each of the outcomes for statistical
modelling. The duration of our study is over 18 years and there
have been significant changes to the clinical practice and post-
operative management of patients, especially with the imple-
mentation of Enhanced Recovery after Surgery (ERAS) pro-
tocols. This has had an impact on the post-operative outcomes
and length of stay of patients [4, 5, 12, 13].
Conclusion
Partial pancreatoduodenectomy with sufficient lymph node
clearance is the only effective treatment for duodenal cancer
achieving longer disease free and overall survival. From a
practice perspective, patients presenting with obstructive jaun-
dice and/or gastric outlet obstruction should not be assumed to
have a poor prognosis but be considered for curative resection
with an emphasis on nutrition and a meticulous operative ap-
proach. Tumour stage and resection margin status are key
independent survival factors indicating a need for effective
neoadjuvant and/or adjuvant treatments.
Table 5 Multivariate Cox model for time to death
Variable Hazard ratio (95% CI) Log-rank χ2 p value
R status
0 1 16.20 < 0.001
1 5.83 (2.25–15.07)
T stage
3- 1 4.22 0.040
4 2.27 (1.02–5.04)
Table 3 Univariate Cox models for time to death
Variable Hazard ratio (95% CI) Log-rank χ2 p value
Gender
Female 1 0.15 0.697
Male 1.15 (0.56–2.36)
Age (years) 1.03 (0.99–1.08) 2.03 0.154
T stage
3− 1 8.59 0.003
4 2.97 (1.39–6.35)
N stage
0 1 1.92 0.166
1+ 1.76 (0.78–3.95)
R status
0 1 25.74 < 0.001
1 7.88 (3.11–19.96)
Albumin (g/L) 0.94 (0.89, 0.99) 5.33 0.021
Gastric outlet obstruction
No 1 4.96 0.026
Yes 2.30 (1.08–4.90)
Obstructive jaundice
No 1 0.26 0.611
Yes 1.25 (0.53–2.96)
Adjuvant treatment
No 1 0.11 0.742
Yes 0.88 (0.40–1.92)
Table 6 Multivariate Cox model for time to recurrence
Variable Hazard ratio (95% CI) Log-rank χ2 p value
R status
0 1 12.68 < 0.001
1 4.48 (1.95–10.28)
T stage
3− 1 3.29 0.070
4 2.28 (1.07–4.86)
Age (years) 1.06 (1.01–1.11) 6.29 0.012
Table 4 Univariate Cox models for time to recurrence
Variable Hazard ratio (95% CI) Log-rank χ2 p value
Gender
Female 1 0.10 0.758
Male 1.12 (0.56–2.23)
Age (years) 1.05 (1.00–1.09) 3.59 0.058
T stage
3− 1 6.82 0.009
4 2.56 (1.23, 5.31)
N stage
0 1 2.34 0.126
1+ 1.85 (0.83, 4.12)
R status
0 1 18.34 < 0.001
1 5.06 (2.23, 11.49)
Albumin (g/L) 0.95 4.57 0.032
(0.90, 1.00)
Gastric outlet obstruction
No 1 3.13 0.077
Yes 1.93 (0.92–4.03)
Obstructive jaundice
No 1 0.02 0.884
Yes 1.07 (0.45, 2.51)
Adjuvant treatment
No 1 0.00 0.975
Yes 0.99 (0.47–2.082)
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